Cargando…

Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer

Histone deacetylase inhibitors (HDACi) sensitize homologous recombination (HR)-proficient human ovarian cancer cells to PARP inhibitors (PARPi). To investigate mechanisms of anti-tumor effects of combined HDACi/PARPi treatment we performed transcriptome analysis in HR- proficient human ovarian cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Andrew J., Gupta, Vijayalaxmi G, Liu, Qi, Yull, Fiona, Crispens, Marta A., Khabele, Dineo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702851/ https://www.ncbi.nlm.nih.gov/pubmed/34933276 http://dx.doi.org/10.1016/j.neo.2021.12.002

Ejemplares similares

Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy
por: Gupta, Vijayalaxmi, et al.
Publicado: (2018)

Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis
por: Hufnagel, Demetra H., et al.
Publicado: (2020)

Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2015)

Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2015)

Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer
por: Hoover, Alyssa A., et al.
Publicado: (2020)

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
por: Petersen, Shariska, et al.
Publicado: (2020)

Blood type, ABO genetic variants, and ovarian cancer survival
por: Cozzi, Gabriella D., et al.
Publicado: (2017)

Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records
por: Cozzi, Gabriella D., et al.
Publicado: (2016)

Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model
por: Wilson, Andrew J, et al.
Publicado: (2013)

Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors
por: Beeghly-Fadiel, Alicia, et al.
Publicado: (2018)

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023)

The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
por: Khabele, Dineo
Publicado: (2014)

Incidental placenta increta at the time of prophylactic hysterectomy for Lynch syndrome: Insights into individualized decision-making and surgical timing
por: Nielsen, Tara A., et al.
Publicado: (2015)

Micelle encapsulation zinc‐doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair
por: Yi, Jingyan, et al.
Publicado: (2023)

Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer
por: Glass, Evan B., et al.
Publicado: (2022)

Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis
por: Matsubara, Nobuaki, et al.
Publicado: (2022)

Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations
por: Wu, Chiao-En, et al.
Publicado: (2021)

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance
por: Wang, Li‐Min, et al.
Publicado: (2023)

Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy
por: Wilson, Andrew J, et al.
Publicado: (2012)

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
por: Choi, Young Eun, et al.
Publicado: (2014)

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer
por: Jewell, Andrea, et al.
Publicado: (2018)

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein
por: Ghiringhelli, Francois, et al.
Publicado: (2016)

Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer
por: Asem, Marwa, et al.
Publicado: (2020)

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro
por: Borchert, Sabrina, et al.
Publicado: (2019)

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial
por: Pujade-Lauraine, Eric, et al.
Publicado: (2023)

Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib
por: Roberts, Cai M., et al.
Publicado: (2023)

A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations
por: Thavaneswaran, Subotheni, et al.
Publicado: (2023)

Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status Phase II LIGHT study primary analysis
por: Cadoo, Karen, et al.
Publicado: (2022)

Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2015)

Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair
por: Ovejero-Sánchez, María, et al.
Publicado: (2021)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model
por: Borst, Gerben R., et al.
Publicado: (2017)

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells
por: Mani, Chinnadurai, et al.
Publicado: (2019)

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer
por: Carr, T. Hedley, et al.
Publicado: (2021)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020)

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model
por: Borst, Gerben R., et al.
Publicado: (2020)

Polymorphism of DNA Repair Genes via Homologous Recombination (HR) in Ovarian Cancer
por: Smolarz, Beata, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair
por: Kong, Yangyang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lgv4dpfti3l9uhtbhqv8pcs4oj